RLS Global AB (publ) Year-end Report, Q4, 2022
OCTOBER 1st – DECEMBER 31st (previous year in brackets)
- Net sales amounted to TSEK 291 (TSEK 219)
- Earnings before interest and taxes (EBIT) amounted to MSEK -7,9 (MSEK -7,8)
- Earnings per share after dilution at SEK -0,10 (SEK 0,09)
- Cash flow from operating activities amounted to TSEK -5 779 (TSEK -4 887)
- Liquid assets at the end of the period MSEK 20,5 ( MSEK 11,5)
- Equity ratio was 83 % (75 %)
JANUARY 1st – DECEMBER 31st (previous year in brackets)
- Net sales amounted to TSEK 1 198 (TSEK 653)
- Earnings before interest and taxes (EBIT) amounted to MSEK -24,3 (MSEK 11,0)
- Earnings per share after dilution at SEK -0,3 (SEK- 0,14)
- Cash flow from operating activities amounted to TSEK -23 569 (TSEK -8 353)
- Liquid assets at the end of the period MSEK 20,5 (MSEK 11,5)
- Equity ratio was 83 % (75 %)
SUMMARY OF EVENTS DURING FIRST QUARTER
- RLS Global’s notified bodies perform quality audits (ISO 13485 and MDD) without remarks
- Karin Fischer hands in her resignation
- Convatec is taking over the agreements with Swedish customers
- ChloraSolv is now delivered to the Convatec central warehouse on a regular basis
- ChloraSolv is reimbursed in the Netherlands
SUMMARY OF EVENTS DURING SECOND QUARTER
- Annual General Meeting is held May 19
- RLS signs distribution contract for Middle East
- RLS introduces ChloraSolv for the animal segment in Scandinavia by signing distribution contract with Swevet
- ChloraSolv is approved for leg ulcers in Kuwait
SUMMARY OF EVENTS DURING THIRD QUARTER
- An article regarding ChloraSolv is published in Journal of Wound Care
- RLS Global strengthens its solvency by transforming a loan to share capital
SUMMARY OF EVENTS DURING FOURTH QUARTER
- Björn Larsson starts as CEO
- RLS carries out a new share issue (rights issue) and thereby raises SEK 26.8 million in cash and cash equivalents after issue costs
- The Swedish Medicines Agency approves RLS’ application for a clinical study regarding pressure ulcers
- RLS takes part in the conference Wounds UK in Harrogate, England
SUMMARY OF EVENTS AFTER FOURTH QUARTER
- An extra General Meeting is held February 9, 2023
- Lars Johansson is elected as Chairman of the Board
- RLS visits Arab Health, a global health conference in the Middle East and performs on-site distributor meetings and training sessions
The Year-end Report Q4, 2022, is enclosed and is also available here.
Publication
This information was submitted for publication through the agency of the below contact person, at 08.30 CET on Feb 28th 2023.
TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.
FOR MORE INFORMATION, PLEASE CONTACT:
Björn Larsson, CEO, RLS Global
E-mail: bjorn.larsson@rlsglobal.se
Tel: +46 766 20 17 25
Eva Jagenheim, CFO, RLS Global
E-mail: eva.jagenheim@rlsglobal.se
Tel: +46 730 23 13 57
ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products under the brand ChloraSolv® for indications within advanced wound care.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as wound care and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company’s platform technology and its unique features will help many patients around the world. Read more at rls.global